Franco Mandelli

31.7k citations
484 papers · 15.2k indexed · h-index 65

Impact in

  • Hematology top 0.02%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
  • Genetics top 0.1%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Acute Myeloid Leukemia Research 203
    • Chronic Myeloid Leukemia Treatments 76
    • Hematopoietic Stem Cell Transplantation 69
    • Multiple Myeloma Research and Treatments 36
    • Chronic Lymphocytic Leukemia Research 114

Franco Mandelli

480 papers receiving 14.7k citations

Peers

Franco Mandelli
Comparison fields: 5 of 151
  • Hematology 9.0k
  • Genetics 3.6k
  • Pathology and Forensic Medicine 2.7k
  • Oncology 3.4k
  • Public Health, Environmental and Occupational Health 3.6k
Replace Charles A. Schiffer with:
Charles A. Schiffer United States
Miguel Á. Sanz Spain
Hillard M. Lazarus United States
Josep‐María Ribera Spain
Jacob M. Rowe Israel
Bayard L. Powell United States
Aloïs Gratwohl Switzerland
Augustin Ferrant Belgium
CD Buckner United States
Donna Przepiorka United States
Franco Mandelli relative to Charles A. Schiffer United States Charles A. Schiffer's profile →
Citations per field
00.5×1.5×
Charles A. Schiffer · 1×
Citations per year

Countries citing papers authored by Franco Mandelli

Since Specialization
Citations

This map shows the geographic impact of Franco Mandelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franco Mandelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franco Mandelli more than expected).

Fields of papers citing papers by Franco Mandelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franco Mandelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franco Mandelli. The network helps show where Franco Mandelli may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Franco Mandelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Franco Mandelli Line = papers co-authored together Franco Mandelli links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 201410
2 2006102
3 200590
4
Survival of elderly patients with acute myeloid leukemia.
200449
5 20047
6 200413
7
Allogeneic vs autologous stem cell transplantation according to cytogenetic and FAB features in AML patients (pts) <=45 yrs old in CRI: Results of the EORTC-GIMEMA AML-10 trial
20022
8
Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial
20015
9
The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial.
20005
10
Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia
19992
11 199916
12
Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first complete remission (CR) after bone marrow transplantation (BMT) - Allogeneic or autologous - Or intensive chemotherapy consolidation (ICC): EORTC-GIMEMA AML 8A study
19951
13
Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings.
19923
14
Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
199234
15
Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients.
199015
16 199041
17
Acute myeloblastic leukemia with t(8;21) following Philadelphia positive acute lymphoblastic leukemia.
19899
18 198938
19
High-dose chemotherapy and autologous stem cell infusion in patients with chronic myelogenous leukaemia in early phase of the disease
19883
20 198718

About Franco Mandelli

Franco Mandelli is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Oncology, having authored 484 papers that have together received 15.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (203 papers), Acute Lymphoblastic Leukemia research (123 papers), Chronic Lymphocytic Leukemia Research (114 papers), Lymphoma Diagnosis and Treatment (98 papers), Chronic Myeloid Leukemia Treatments (76 papers), Hematopoietic Stem Cell Transplantation (69 papers), Retinoids in leukemia and cellular processes (63 papers) and Multiple Myeloma Research and Treatments (36 papers). The work is most often cited by research in Hematology (9.0k citations), Genetics (3.6k citations), Pathology and Forensic Medicine (2.7k citations), Oncology (3.4k citations) and Public Health, Environmental and Occupational Health (3.6k citations). Franco Mandelli has collaborated with scholars based in Italy, Netherlands and France. Frequent co-authors include Giuseppe Avvisati, Sergio Amadori, Giovanna Meloni, Marco Vignetti, Maria Concetta Petti, Francesco Lo‐Coco, Edoardo Pescarmona, Francesca Romana Mauro, Daniela Diverio and Robin Foà. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia Research, Leukemia and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026